LOgo.png
Serina Therapeutics to Present at the 14th Annual Injectables Summit
02 oct. 2024 08h30 HE | Serina Therapeutics, Inc.
HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
LOgo.png
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 18h42 HE | Serina Therapeutics, Inc.
HUNTSVILLE, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
LOgo.png
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit
29 juil. 2024 08h30 HE | Serina Therapeutics, Inc.
HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug delivery...
LOgo.png
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation
18 juil. 2024 17h00 HE | Serina Therapeutics, Inc.
HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
LOgo.png
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
14 mai 2024 16h05 HE | Serina Therapeutics, Inc.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
LOgo.png
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
26 mars 2024 17h04 HE | Serina Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the...